CD274 and neoplasm: Currently, three FDA-approved biomarkers, indicative for ICIs treatment in cancers, are PD-L1 positivity by immunohistochemistry, MSI status, and tumour mutational burden, although the efficacy of the latter two has been challenged in several studies, as mentioned above.